Tumor control (TC), toxicity and survival, following stereotactic body radiation therapy (SBRT) were compared between patients with and without a prior lung resection (PLR).
The study is comprised of 130 patients with 141 peripheral tumors treated with SBRT at our institution from 2009 to 2013. Primary TC and lobar control (LC) were defined per RTOG 0236. Toxicity was scored using Common Terminology Criteria for Adverse Events version 4.0. Survival/TC and toxicity were compared between patients with and without PLR using the Kaplan-Meier method and cumulative incidence, respectively. Fine and Gray regression was used for univariable/multivariable analysis for radiation pneumonitis (RP).
Of the 130 patients with median age 70 years (range, 42 to 93 y), 50 had undergone PLR (median time between PLR and SBRT: 33 mo; range, 1 to 206), including pneumonectomy (12%), lobectomy (46%), wedge resection (42%). With a median follow-up of 21 months in survivors, the PLR group had better TC (1-y 100% vs. 93%; P<0.01) and increased grade ≥2 (RP; 1-y 12% vs. 1%; P<0.01). OS was not significantly different between the 2 groups (1-y 91% vs. 85%; P=0.24). On univariable/multivariable analyses, biologically effective dose was associated with TC (hazard ratios, 0.97; 95% confidence interval, 0.94-0.999; P=0.04). Chemotherapy use was associated with grade ≥2 RP for all patients (hazard ratios, 14.92; 95% confidence interval, 5.68-39.21; P<0.0001) in multivariable analysis. PLR was not associated with increased RP in multivariable analysis.
Patients with PLR who receive lung SBRT for lung tumors have high local control and relatively low toxicity. SBRT is an excellent option to treat second lung tumors or pulmonary metastases in patients with PLR.
Departments of *Radiation Oncology
‡Radiology, Dana-Farber Cancer Institute/Brigham and Women’s Hospital
†Harvard Medical School
∥Division of Thoracic Surgery, Brigham and Women’s Hospital, Boston, MA
§Department of Radiation Oncology (MAASTRO), GROW Research Institute, Maastricht University, Maastricht, The Netherlands
This work was funded in part by a Kaye Award.
Presented as a poster at ASTRO 2014.
R.H.M. has stock ownership of Celgene Inc. The other authors declare no conflicts of interest.
Reprints: Raymond H. Mak, MD, Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Harvard Medical School, 450 Brookline Ave., JF518, Boston, MA 02115-5450. E-mail: firstname.lastname@example.org.